Workflow
Petco Health and Wellness pany(WOOF) - 2024 Q3 - Quarterly Report

Financial Performance - Net sales decreased from 1.50billionto1.50 billion to 1.49 billion, a period-over-period decrease of 0.5%[90] - Operating loss of 1,232.1millionprimarilyduetogoodwillimpairmentof1,232.1 million primarily due to goodwill impairment of 1,222.5 million, compared to operating income of 48.1millionintheprioryear[90]NetlossattributabletoClassAandB1commonstockholderswas48.1 million in the prior year[90] - Net loss attributable to Class A and B-1 common stockholders was 1,241.1 million, compared to net income of 19.9millionintheprioryear[90]AdjustedEBITDAdecreasedfrom19.9 million in the prior year[90] - Adjusted EBITDA decreased from 120.2 million to 72.2million[90]Grossprofitmargindecreasedto36.872.2 million[90] - Gross profit margin decreased to 36.8% from 39.8% in the prior year[92] - Comparable sales change was 0.0% for the thirteen weeks ended October 28, 2023, and 4.1% for the thirty-nine weeks ended[92] - Net sales decreased by 7.1 million, or 0.5%, to 1.49billionforthethirteenweeksendedOctober28,2023,whileincreasingby1.49 billion for the thirteen weeks ended October 28, 2023, while increasing by 122.8 million, or 2.8%, to 4.58billionforthethirtynineweeksendedOctober28,2023[93]Grossprofitdecreasedby4.58 billion for the thirty-nine weeks ended October 28, 2023[93] - Gross profit decreased by 47.7 million, or 8.0%, to 550.0millionforthethirteenweeksendedOctober28,2023,withagrossprofitrateof36.8550.0 million for the thirteen weeks ended October 28, 2023, with a gross profit rate of 36.8% compared to 39.8% in the prior year[98] - Adjusted EBITDA for the thirteen weeks ended October 28, 2023, was 72.2 million, down from 120.2millionforthesameperiodin2022,representingadecreaseof40120.2 million for the same period in 2022, representing a decrease of 40%[113] - Net sales for the thirty-nine weeks ended October 28, 2023, were 4.58 billion, compared to 4.46billionforthesameperiodin2022,reflectingayearoveryearincreaseof2.74.46 billion for the same period in 2022, reflecting a year-over-year increase of 2.7%[113] - The company reported a net loss attributable to Class A and B-1 common stockholders of (1.24) billion for the thirteen weeks ended October 28, 2023, compared to a profit of 19.9millionforthesameperiodin2022[113]SalesandRevenueBreakdownTotalnetsalesforthethirteenweeksendedOctober28,2023,included19.9 million for the same period in 2022[113] Sales and Revenue Breakdown - Total net sales for the thirteen weeks ended October 28, 2023, included 1,257.8 million from products and 236.4millionfromservicesandother[91]Consumablessalesincreasedby236.4 million from services and other[91] - Consumables sales increased by 12.8 million, or 1.8%, to 733.3millionforthethirteenweeksendedOctober28,2023,drivenbyadditionalbrandsintheassortment[93]Servicerelatedsales,includingveterinaryhospitals,increasedby14.0733.3 million for the thirteen weeks ended October 28, 2023, driven by additional brands in the assortment[93] - Service-related sales, including veterinary hospitals, increased by 14.0% and 14.6% for the thirteen and thirty-nine weeks ended October 28, 2023, respectively[96] - E-commerce and digital sales increased by 4.7% and 8.4% for the thirteen and thirty-nine weeks ended October 28, 2023, respectively, driven by online initiatives[96] Expenses and Cash Flow - SG&A expenses increased by 10.0 million, or 1.8%, to 559.6millionforthethirteenweeksendedOctober28,2023,representing37.5559.6 million for the thirteen weeks ended October 28, 2023, representing 37.5% of net sales[99] - Interest expense increased by 9.3 million, or 33.9%, to 36.6millionforthethirteenweeksendedOctober28,2023,primarilyduetohigherinterestrates[103]FreeCashFlowforthethirtynineweeksendedOctober28,2023,was36.6 million for the thirteen weeks ended October 28, 2023, primarily due to higher interest rates[103] - Free Cash Flow for the thirty-nine weeks ended October 28, 2023, was (7.8) million, compared to (2.6)millionforthesameperiodin2022,indicatingadeclineincashgeneration[116]Netcashprovidedbyoperatingactivitiesdecreasedto(2.6) million for the same period in 2022, indicating a decline in cash generation[116] - Net cash provided by operating activities decreased to 168.7 million for the thirty-nine weeks ended October 28, 2023, from 209.5millionforthesameperiodin2022,drivenbylowerearningsandincreasedcashoutflows[122]Financingactivitiesresultedinanetcashoutflowof209.5 million for the same period in 2022, driven by lower earnings and increased cash outflows[122] - Financing activities resulted in a net cash outflow of 84.0 million for the thirty-nine weeks ended October 28, 2023, compared to 27.0millionforthesameperiodin2022,primarilyduetoprincipalrepaymentsonthetermloan[125]GoodwillandImpairmentGoodwillimpairmentchargeof27.0 million for the same period in 2022, primarily due to principal repayments on the term loan[125] Goodwill and Impairment - Goodwill impairment charge of 1.22 billion was recorded during the thirteen weeks ended October 29, 2022, due to an interim impairment test[101] - The company incurred 1.22billioningoodwillimpairmentduringthethirteenweeksendedOctober28,2023,whichsignificantlyimpactednetincome[113]LiquidityandDebtTheliquiditypositionasofOctober28,2023,was1.22 billion in goodwill impairment during the thirteen weeks ended October 28, 2023, which significantly impacted net income[113] Liquidity and Debt - The liquidity position as of October 28, 2023, was 586.4 million, which includes cash and cash equivalents of 139.8millionand139.8 million and 446.6 million available on the ABL Revolving Credit Facility[118] - As of October 28, 2023, the Company had 1,595.3millionoutstandingundertheFirstLienTermLoan[141]A100basispointsincreaseinvariableratesontheFirstLienTermLoanandABLRevolvingCreditFacilitywouldincreaseannualcashinterestbyapproximately1,595.3 million outstanding under the First Lien Term Loan[141] - A 100 basis points increase in variable rates on the First Lien Term Loan and ABL Revolving Credit Facility would increase annual cash interest by approximately 16.2 million[142] - The Company has no amounts outstanding under the ABL Revolving Credit Facility as of October 28, 2023[142] - The Company maintains cash and cash equivalents at major financial institutions, likely exceeding insured limits, with minimal credit risk[144] Business Operations - Total pet care centers at the end of the period remained stable at 1,429[92] - Total veterinarian practices increased to 282 from 229 in the prior year[92] - The company operates over 275 veterinary hospitals, contributing to the growth in its veterinary and grooming business[95] Taxation - The effective tax rate was 1.8% for the thirteen weeks ended October 28, 2023, resulting in an income tax benefit of $22.9 million, compared to an effective tax rate of 17.3% in the prior year[106] Market Conditions - Substantially all business is conducted in U.S. dollars, with no material effect expected from a 10% fluctuation in the relative value of the U.S. dollar[145]